New microneedle arrays for better delivery of treatments to the brain
Official title: 3D microprinting-enabled microinjection needle arrays for enhanced therapeutics delivery into the brain
Funded at Seetrue Technology, LLC · NIH-10761073 · Data updated 2026-11-12
This study is working on a new way to deliver treatments directly into the brain using tiny microneedles, which could help people with conditions like cancer and neurodegenerative diseases by making therapies more effective and easier on the body.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seetrue Technology, LLC NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | September 10, 2023 |
| Project end | September 9, 2025 |
| Funding year | 2023 |
| Award (this year) | $403,847 |
| NIH project number | 1R41MH135827-01 |
| Project ID | NIH-10761073 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from neurological conditions such as cancer, traumatic brain injury, or neurodegenerative diseases.
✕Less likely to help
Patients with conditions unrelated to brain therapies or those who are not candidates for gene or cell therapy may not benefit from this research.
What this research studies
This research focuses on developing innovative microneedle arrays that enhance the delivery of gene and cell therapies directly into brain tissues. By addressing the limitations of traditional microinjection needles, which can cause tissue damage and uneven distribution of therapeutics, this project aims to create a more effective method for treating neurological conditions such as cancer and neurodegenerative diseases. The approach involves designing microneedles that can deliver multiple therapeutic agents simultaneously, improving treatment efficacy and minimizing side effects. Patients may benefit from more effective and targeted therapies as a result of this advancement.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for brain-related conditions, improving patient outcomes.
How similar studies have gone: While the approach of using microneedle arrays is innovative, similar technologies have shown promise in other areas of drug delivery, indicating potential for success.
Where this research is happening
-
Seetrue Technology, LLC
Rockville, United States Active
Researchers
- Principal investigator: Rand, Kinneret — Seetrue Technology, LLC
- Study coordinator: Rand, Kinneret
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.